Sort   by:  
 Page size 
TranscriptomicsCombined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma
Melanoma is the deadliest form of skin cancer. MAPK-targeted therapies (MAPKi) and immune checkpoint inhibitors (ICI) have shown clinical benefit but are limited by resistance mechanisms that remain poorly defined. MNK1/2 inhibitors (MNKi) have shown promising effects in pre-clinical tumor models, p...
ORGANISM(S): Homo sapiens 
2024-06-30 | GSE260507 | GEO
Genomics
Mouse Spinal Cord Transcriptome from WT, miR-155 MNKI, and miR-128 GLKO 1h and 4h after Aortic Cross Clamping
PRJNA1097603 | ENA
ProteomicsCombined inhibition of MNK signaling and BET proteins reveals TGM2 as a novel vulnerability in melanoma
Melanoma is the deadliest form of skin cancer. MAPK-targeted therapies (MAPKi) and immune checkpoint inhibitors (ICI) have shown clinical benefit but are limited by resistance mechanisms that remain poorly defined. MNK1/2 inhibitors (MNKi) have shown promising effects in pre-clinical tumor models, p...
ORGANISM(S): Homo sapiens (Human) 
2024-10-01 | PXD044698 | Pride
Proteomics Tgm2 Mnk Lfq Melanoma Dda Bet Fak 
GenomicsCombined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma
Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma
PRJNA1081910 | ENA
ProteomicsMorpholino nicotinamide analogs of ponatinib, dual MNK, p70S6K inhibitors, display efficacy against lung and breast cancers
Global and phosphoproteomic analysis to identify and characterize oncogenic pathways differentially regulated by the MNK/p70S6Ki, HSND80
ORGANISM(S): Homo sapiens (Human) 
2025-03-27 | PXD057373 | Pride
Anticancer Kinase inhibitor Tnbc Small molecules Mnki Nsclc P70s6ki 
Sort   by:  
 Page size